Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
MLYS 
Mineralys Therapeutics, Inc. Common Stock (MLYS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/24/2025: MLYS (4-star) is a STRONG-BUY. BUY since 43 days. Simulated Profits (164.06%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $43.75
1 Year Target Price $43.75
| 6 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 78.59% | Avg. Invested days 31 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 10/24/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.10B USD | Price to earnings Ratio - | 1Y Target Price 43.75 |
Price to earnings Ratio - | 1Y Target Price 43.75 | ||
Volume (30-day avg) 8 | Beta 0.4 | 52 Weeks Range 8.24 - 44.80 | Updated Date 10/25/2025 |
52 Weeks Range 8.24 - 44.80 | Updated Date 10/25/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.56 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -38.8% | Return on Equity (TTM) -63.21% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2813553778 | Price to Sales(TTM) - |
Enterprise Value 2813553778 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -7.41 | Shares Outstanding 77569693 | Shares Floating 46169292 |
Shares Outstanding 77569693 | Shares Floating 46169292 | ||
Percent Insiders 1.82 | Percent Institutions 100.32 |
Upturn AI SWOT
Mineralys Therapeutics, Inc. Common Stock
Company Overview
History and Background
Mineralys Therapeutics, Inc. is a biopharmaceutical company focused on developing medicines to treat diseases driven by abnormally elevated levels of aldosterone. Founded in 2020, it went public in 2023.
Core Business Areas
- Drug Development: Focuses on developing therapies targeting aldosterone synthase for hypertension and related cardiovascular and kidney diseases.
Leadership and Structure
The leadership team includes Jon Congleton (CEO) and other key executives in drug development and operations. The company operates with a structure typical of a clinical-stage biopharmaceutical company, focusing on research, clinical trials, and regulatory affairs.
Top Products and Market Share
Key Offerings
- Lorundrostat (MRL-101): A selective aldosterone synthase inhibitor (ASI) being developed for the treatment of hypertension. Currently in Phase 2 clinical trials. No current market share as it is still in development. Competitors include existing hypertension medications (ACE inhibitors, ARBs, diuretics) and other companies developing aldosterone-targeting therapies.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive, particularly in the cardiovascular and renal disease space. There is a significant unmet need for effective hypertension treatments, especially for patients who are resistant to existing therapies.
Positioning
Mineralys is positioning itself as a leader in aldosterone-targeted therapies for hypertension, addressing a specific mechanism of disease not adequately addressed by existing drugs.
Total Addressable Market (TAM)
The TAM for hypertension therapies is substantial, estimated in the tens of billions of dollars globally. Mineralys is focused on a subset of patients with aldosterone-mediated hypertension, representing a significant portion of this overall market. Their positioning leverages a novel mechanism of action.
Upturn SWOT Analysis
Strengths
- Novel therapeutic target (aldosterone synthase)
- Strong intellectual property position
- Experienced management team
- Positive early clinical trial data
Weaknesses
- Single product pipeline
- Clinical trial risk
- Reliance on successful regulatory approval
- Limited commercialization experience
Opportunities
- Expansion into other aldosterone-driven diseases
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results leading to accelerated approval
- Acquisition by a larger pharma company
Threats
- Clinical trial failures
- Competition from other hypertension drugs
- Regulatory hurdles
- Patent challenges
- Adverse side effects discovered during trails
Competitors and Market Share
Key Competitors
- AZN
- NVS
- BMY
Competitive Landscape
Mineralys faces competition from established hypertension medications and companies developing other novel treatments. Its competitive advantage lies in its selective aldosterone synthase inhibitor, which targets a specific mechanism of disease.
Growth Trajectory and Initiatives
Historical Growth: Growth is measured by progress in clinical trials and pipeline development.
Future Projections: Future growth depends on successful completion of clinical trials, regulatory approval, and commercialization. Analyst estimates vary based on the probability of success.
Recent Initiatives: Focus on advancing Lorundrostat (MRL-101) through Phase 2 clinical trials and exploring potential indications beyond hypertension.
Summary
Mineralys Therapeutics is a clinical-stage biopharmaceutical company with a focus on developing novel therapies for hypertension. Their lead product candidate, Lorundrostat, shows promise in targeting aldosterone synthase. The company faces significant clinical trial and regulatory risks but also has the potential for substantial growth if successful. Financial performance is currently driven by R&D spending and fundraising efforts, making future growth dependent on positive trial outcomes and strategic partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Clinical trial data
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment in biopharmaceutical companies is inherently risky.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Mineralys Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters Radnor, PA, United States | ||
IPO Launch date 2023-02-10 | President, CEO & Director Mr. Jon Congleton | ||
Sector Healthcare | Industry Biotechnology | Full time employees 51 | Website https://mineralystx.com |
Full time employees 51 | Website https://mineralystx.com | ||
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. The company's clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. It has initiated a Phase 2 trial for lorundrostat in hypertensive patients with stage 2 to 3b chronic kidney disease and a pivotal clinical program of lorundrostat for the treatment of uncontrolled or resistant hypertension. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.